دورية أكاديمية
أعرض في EDS

NAT1 inhibits liver metastasis of colorectal cancer by regulating EMT and glycolysis.

التفاصيل البيبلوغرافية
العنوان: NAT1 inhibits liver metastasis of colorectal cancer by regulating EMT and glycolysis.
المؤلفون: Gu W; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Li C; Department of Biology, Chemistry, Pharmacy, Free University of Berlin, Berlin 14195, Germany., Shen T; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Tong L; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Yuan W; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Zheng X; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Wang T; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Wang S; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Zhu B; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Zhang C; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China., Zhang C; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
المصدر: Aging [Aging (Albany NY)] 2024 Jun 24; Vol. 16 (12), pp. 10546-10562. Date of Electronic Publication: 2024 Jun 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Albany, NY : Impact Journals, LLC
مواضيع طبية MeSH: Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/metabolism , Epithelial-Mesenchymal Transition*/genetics , Glycolysis* , Liver Neoplasms*/secondary , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Arylamine N-Acetyltransferase*/genetics , Arylamine N-Acetyltransferase*/metabolism , Signal Transduction*, Humans ; Animals ; Cell Line, Tumor ; Mice ; TOR Serine-Threonine Kinases/metabolism ; Isoenzymes/metabolism ; Isoenzymes/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor A/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Gene Expression Regulation, Neoplastic ; Mice, Nude
مستخلص: Metastasis is the primary cause of cancer-related deaths, and colorectal cancer (CRC) liver metastasis is a major poor prognostic factor in CRC. NAT1 (N-acetyltransferase 1) plays a crucial role in the invasive and metastatic processes of colorectal cancer. The role and molecular mechanism of NAT1 on tumor cells were verified by establishing a cell model of overexpression and knockdown of NAT1, and further verified by establishing a liver metastasis model of colorectal cancer for animal experiments. In vivo and in vitro experiments have demonstrated that overexpression of NAT1 reduces the ability of metastasis and invasion of colorectal cancer cells. NAT1 overexpression inhibits the PI3K/AKT/mTOR signaling pathway, thereby suppressing the EMT (epithelial-mesenchymal transition) process and glycolytic ability of tumor cells. Additionally, decreased glycolytic ability results in reduced VEGF (Vascular endothelial growth factor) expression in colorectal cancer cells. The decreased VEGF expression leads to decreased angiogenesis and vascular permeability in liver metastases, ultimately reducing the occurrence of liver metastasis. Our findings highlight that overexpression of NAT1 significantly inhibits the PI3K/AKT/mTOR signaling pathway, thereby suppressing EMT, glycolytic ability, and VEGF expression in colorectal cancer cells, collectively preventing the development of liver metastasis.
References: Nat Commun. 2015 Aug 10;6:7882. (PMID: 26258887)
PLoS One. 2015 Sep 16;10(9):e0138213. (PMID: 26375396)
Lancet. 2019 Oct 19;394(10207):1467-1480. (PMID: 31631858)
J Hepatol. 2011 Oct;55(4):846-57. (PMID: 21334407)
Cell Metab. 2008 Jan;7(1):11-20. (PMID: 18177721)
Int J Oncol. 2018 Aug;53(2):694-702. (PMID: 29901116)
Biochem Biophys Res Commun. 2010 Feb 26;393(1):95-100. (PMID: 20100460)
EMBO Rep. 2008 Jun;9(6):582-9. (PMID: 18483486)
Clin Exp Pharmacol Physiol. 2018 Dec;45(12):1265-1273. (PMID: 30044005)
Cancer Med. 2015 Apr;4(4):565-74. (PMID: 25627111)
Am J Cancer Res. 2020 Aug 01;10(8):2464-2479. (PMID: 32905535)
Future Oncol. 2021 Jul;17(19):2489-2498. (PMID: 33906370)
Exp Mol Med. 2016 Jun 10;48:e238. (PMID: 27282106)
Pharmacol Rev. 2012 Jan;64(1):147-65. (PMID: 22090474)
PLoS One. 2011 Feb 09;6(2):e17031. (PMID: 21347396)
Nature. 2015 May 14;521(7551):S1. (PMID: 25970450)
Hepatology. 2015 Oct;62(4):1145-59. (PMID: 26082033)
J Mol Cell Cardiol. 1990 Dec;22(12):1393-404. (PMID: 2089157)
Cell. 2008 Sep 5;134(5):703-7. (PMID: 18775299)
Semin Cancer Biol. 2022 Nov;86(Pt 3):251-261. (PMID: 35307547)
Cell. 2013 Aug 1;154(3):651-63. (PMID: 23911327)
Hepatology. 2013 Jul;58(1):229-38. (PMID: 23463346)
J Mol Cell Biol. 2016 Oct 1;8(5):400-410. (PMID: 27001970)
Oncogene. 2017 Mar 30;36(13):1779-1792. (PMID: 27641329)
Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42. (PMID: 10667461)
J Immunol. 2010 Feb 1;184(3):1200-9. (PMID: 20026743)
Autophagy. 2018;14(4):685-701. (PMID: 29165041)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cancer Biol Med. 2020 Feb 15;17(1):101-111. (PMID: 32296579)
Eur J Surg Oncol. 2006 Jun;32(5):473-83. (PMID: 16580172)
Cancer Metab. 2014 Sep 15;2:19. (PMID: 25250177)
Mol Cell Biol. 2015 Jan;35(1):2-10. (PMID: 25348713)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
PLoS Biol. 2015 Jul 16;13(7):e1002202. (PMID: 26181372)
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3747-3754. (PMID: 30046816)
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (PMID: 24556840)
Clin Cancer Res. 2007 Dec 1;13(23):7003-11. (PMID: 18056176)
Biomark Insights. 2010 Oct 27;5:103-18. (PMID: 21082037)
Oncogene. 2011 Mar 24;30(12):1436-48. (PMID: 21057535)
J Zhejiang Univ Sci B. 2008 Sep;9(9):701-6. (PMID: 18763302)
Mutat Res. 2002 Sep 30;506-507:65-77. (PMID: 12351146)
Nat Rev Cancer. 2011 Feb;11(2):85-95. (PMID: 21258394)
Cell Death Dis. 2018 May 10;9(5):549. (PMID: 29748591)
Gut. 2022 Mar;71(3):509-520. (PMID: 33758004)
Cell Metab. 2013 May 7;17(5):745-55. (PMID: 23623748)
Dis Model Mech. 2011 Nov;4(6):727-32. (PMID: 22065843)
Mol Carcinog. 2018 Nov;57(11):1458-1466. (PMID: 29964355)
Clin Cancer Res. 2002 Oct;8(10):3039-45. (PMID: 12374670)
Carcinogenesis. 1993 Aug;14(8):1633-8. (PMID: 8353847)
فهرسة مساهمة: Keywords: NAT1; VEGF; colorectal cancer (CRC); epithelial-mesenchymal transition (EMT); glycolysis; liver metastasis
المشرفين على المادة: EC 2.3.1.5 (Arylamine N-Acetyltransferase)
EC 2.3.1.5 (N-acetyltransferase 1)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
0 (Isoenzymes)
EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
0 (Vascular Endothelial Growth Factor A)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
تواريخ الأحداث: Date Created: 20240625 Date Completed: 20240705 Latest Revision: 20240712
رمز التحديث: 20240712
مُعرف محوري في PubMed: PMC11236320
DOI: 10.18632/aging.205957
PMID: 38916406
قاعدة البيانات: MEDLINE
الوصف
تدمد:1945-4589
DOI:10.18632/aging.205957